Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 17, 2025
Reporting Period: Event-based report regarding Nasdaq listing compliance status.
Key Financial Metrics
- Stockholders' Equity (as of Sept 30, 2025): $1,394,161 (Non-compliant with Nasdaq minimum of $2,500,000).
- Recent Capital Raise: Approximately $2.5 million in gross proceeds from a private placement consummated on November 4, 2025.
- Current Compliance Status: Management believes the company has regained compliance with the Stockholders' Equity Requirement as of the filing date.
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for these metrics.
Material Changes
The primary material change is the restoration of compliance with Nasdaq Listing Rule 5550(b)(1). The company previously failed to meet the $2.5 million minimum stockholders' equity requirement based on its Q3 2025 10-Q filing. This deficiency was addressed through a private placement of approximately $2.5 million completed on November 4, 2025.
Outlook, Risks, and Contingencies
- Delisting Risk: The Nasdaq Listing Qualifications staff will continue to monitor compliance. If the company fails to evidence compliance in its next periodic report, it may be subject to delisting.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks such as stock price volatility, cost management, and general market conditions that could affect future performance and listing status.
- Management Commentary: The Interim CEO, Christopher Cooper, signed the report confirming the belief that equity requirements are now met.
Investor Verification Checklist
- Verify the final net proceeds of the November 4, 2025 private placement after deducting placement agent fees and offering expenses.
- Confirm the updated stockholders' equity balance in the next periodic report (10-Q or 10-K) to ensure continued Nasdaq compliance.
- Review the terms of the private placement for any dilution effects or covenants attached to the new capital.
- Monitor Nasdaq communications for any formal determination regarding the company's listing status.